α-突触核蛋白种子扩增检测在认知障碍队列中的诊断表现及与脑脊液和血浆标志物的交互作用
这项回顾性单中心横断面研究纳入640例认知障碍患者,评估脑脊液α-突触核蛋白种子扩增检测(αSAA)对路易体痴呆(DLB)的诊断性能。αSAA诊断DLB的敏感度为95.7%、特异度为93.2%、总体准确率为93.6%;AD患者中9.5%为αSAA阳性,AD与αSyn共病理与认知及生物标志物特征相关。
要点
- αSAA对DLB具有高诊断准确率,支持其临床用于检测αSyn病理。
- AD患者中9.5%αSAA阳性,常伴DLB核心特征及更高APOE ε4频率。
核心结论
- αSAA对DLB诊断准确率高,支持其临床实用性。
- AD-DLB共病理与独特的认知和生物标志物特征相关,病理水平影响临床表型。
研究设计与样本
- 回顾性、单中心、横断面观察性队列研究,纳入2009至2024年西班牙三级记忆门诊的认知障碍个体共640例。
- 参与者包括AD 337例、DLB 92例、额颞叶变性79例、非神经退行性认知障碍100例及认知未受损对照32例。
- αSAA在首次评估时采集的脑脊液样本上进行。
主要发现
- αSAA诊断DLB的敏感度为95.7%(95%CI 91.6%-99.8%),特异度为93.2%(95%CI 90.4%-96.0%),总体诊断准确率为93.6%。
- AD患者中9.5%为αSAA阳性,这些个体更常出现DLB核心特征、APOE ε4频率更高且血浆p-tau217升高。
- αSAA阳性的AD受试者p-tau217和脑脊液p-tau181显著高于DLB伴AD病理的患者。
临床怎么用
- αSAA可用于临床辅助诊断DLB,尤其在认知障碍患者中识别αSyn病理。
- 对AD患者检测αSAA有助于发现αSyn共病理,提示需综合评估临床与生物标志物特征。
- AD与DLB共病理患者认知损害更重且神经退行性标志物更高,提示需个体化诊疗策略。
局限性
- 本研究为回顾性、单中心、横断面设计,结果需在前瞻性多中心队列中验证。
- αSAA仅基于脑脊液样本,未评估其他体液或组织的检测性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles. This study contributes to the understanding of αSAA diagnostic performance for DLB and for detecting αSyn copathology in AD in a real-world memory clinic cohort, using both clinical and biomarker-based classifications. METHODS: This was a retrospective, single-center, cross-sectional observational cohort study of cognitively impaired individuals who attended a tertiary memory clinic in Spain between 2009 and 2024. Participants had neurodegenerative and non-neurodegenerative cognitive decline. αSAA was performed on CSF samples collected at first evaluation. The diagnostic performance of the assay for DLB and associations between AD/αSyn copathology, clinical features, and fluid biomarkers (phosphorylated-tau217 [p-tau217], glial fibrillary acidic protein, neurofilament light chain [NfL]) were analyzed in AD and DLB participants. Diagnostic performance of the test was assessed using standard contingency tables and interactions between biomarkers and clinical features with age, sex, and APOE-adjusted analysis of covariance. RESULTS: A total of 640 participants were included (mean age 67.8 years, 48% female) with clinical diagnoses of AD (n = 337), DLB (n = 92), frontotemporal lobar degeneration (n = 79), non-neurodegenerative cognitive impairment (n = 100), and cognitively unimpaired controls (n = 32). αSAA exhibited a 95.7% sensitivity (95% CI 91.6%-99.8%), 93.2% specificity (95% CI 90.4%-96.0%), and a 93.6% overall diagnostic accuracy for DLB. Among patients with AD, 9.5% were αSAA positive; these individuals more often had core DLB features at presentation, higher APOE ε4 frequency, and elevated plasma p-tau217. Fifty percent of DLB patients showed AD copathology, associated with lower Mini-Mental State Examination scores, higher APOE ε4 prevalence, and higher CSF and plasma NfL. αSAA+ AD subjects had significantly higher p-tau217 and CSF p-tau181 than DLB AD+ patients. DISCUSSION: αSAA demonstrated high diagnostic accuracy for DLB, supporting its clinical utility. AD-DLB copathology is associated with distinct cognitive and biomarker profiles, with varying levels of pathology shaping the clinical phenotype (AD- or DLB-predominant). These findings highlight the need for tailored diagnostic and therapeutic approaches.
引用
- Esteller-Gauxax D, Pérez Millan A, Sarto J, et al. α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers. Neurology. 2025. PMID: 40921019. doi:10.1212/WNL.0000000000214040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。